Toward Stopping MERS Spread

Independent teams culture the Middle East respiratory system coronavirus and identify human antibodies that could inform therapies.

Written byTracy Vence
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Micrograph of MERS-CoV particles (yellow)FLICKR, NIAIDLast week, Saudi Arabian officials announced the 105th Middle East respiratory syndrome (MERS)-related death in the country since the causative coronavirus (CoV) emerged in the country in September 2012. While at first the MERS-CoV was largely a mystery, scientists have since been working to scan its genome, decipher its transmissibility, identify potential vectors, and develop vaccines against it. This week, two independent teams have advanced scientists’ understanding of the coronavirus: one group cultured the MERS-CoV, while another identified human antibodies that bind it and could inform therapies.

In February, Columbia University’s Ian Lipkin and his colleagues showed that MERS-CoV was common in camels living near areas where most of the documented human infections had occurred. Now, Lipkin’s team has identified diverse MERS-CoV quasispecies from Saudi Arabian camels. The researchers’ work was published in mBio this week (April 29).

“There appears to be a wide range of different viruses present within camels,” Lipkin told the University of Minnesota Center for Infectious Disease Research and Policy’s CIDRAP News.

“The finding of infectious virus strengthens the argument that dromedary camels are reservoirs for MERS-CoV,” coauthor Thomas Briese, also of Columbia University, said in a statement. “The narrow range of MERS viruses in humans and a very broad range in camels may explain in part why ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies